~~<i id='30318D707B'><strike id='30318D707B'><tt id='30318D707B'><pre id='30318D707B'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：explore 2025-09-28 10:52:30 Page View：6

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 'Brian's Song' at 50 still offers lessons about cancer for today
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Doctors push to include dialysis machines in emergency stockpile

ArielBrigham,whowasunabletoaccessdialysisduringHurricaneHarveyin2017,posesforaportraitinherhome.Mich

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Restaurant meals are packed with calories, and we still keep eating them

Astudyfoundthat92percentoffoodpopularwitheatersdiningoutexceedthethresholdofcaloriesforanormalmeal.H